

CURRICULUM VITAE

José Javier Fuster, Ph.D.

Office Address: Melchor Fernández Almagro 3
28029 - Madrid (Spain)

Phone: (+34) 914531200

Fax: (+34) 914531265

e-mail: jjfuster@cnic.es

CURRENT POSITION: Associate Professor and Group Leader
Hematovascular Pathophysiology Laboratory
Centro Nacional de Investigaciones Cardiovasculares/
Spanish National Center for Cardiovascular Research (CNIC)

EDUCATION AND ACADEMIC TRAINING:

09/2000-07/2005 B.S. (Biochemistry) University of Valencia, Spain

09/2005-07/2010 Ph.D. (Mol. Bio. Gen.) University of Valencia, Spain

POSTDOCTORAL TRAINING:

08/2010-08/2011 Postdoctoral Associate Spanish National Cardiovascular Research Center

09/2011-06/2015 Postdoctoral Fellow Boston University School of Medicine

ACADEMIC APPOINTMENTS:

07/2015-05/2017 Instructor Boston University School of Medicine (BU, USA)

06/2017-01/2018 Assistant Professor Boston University School of Medicine (BU, USA)

01/2018-08/2018 Assistant Professor Univ. of Virginia School of Medicine (UVA, USA)

09/2018-11/2023 Assistant Professor Spanish National Center for CV Research (CNIC)

09/2020-07/2022 Honorary Professor Autonomous University of Madrid (UAM, Spain)

12/2023-present Associate Professor Spanish National Center for CV Research (CNIC)

PERSONAL STATEMENT OF RESEARCH INTERESTS

My research is focused on the elucidation of new mechanisms that link aging to inflammation and cardiovascular disease (CVD), with an especial interest in the pathophysiology of atherosclerosis and heart failure. Within this setting, my current main line of research is aimed at investigating the potential causal role of age-related somatic mutations in blood cells in cardiovascular and metabolic disease. The accumulation of somatic mutations over time is a hallmark of aging in many tissues, particularly in highly proliferative tissues such as the hematopoietic system. It has been estimated that a middle-age individual carries on the order of 1 million different acquired mutations in the hematopoietic stem cell pool, which sets the stage for a robust Darwinian selection of mutations that provide a competitive advantage to the mutant cell. This phenomenon, known as somatic mutation-driven clonal hematopoiesis (CH), has been associated with an increased risk of atherosclerotic CVD, suggesting the provocative hypothesis that somatic mutations in blood cells contribute to atherosclerosis and related conditions. Testing this hypothesis using a combination of human studies, animal models and cell culture experiments is the main objective of my research. I have conducted pioneering work in this field, providing the first experimental evidence causally linking CH to accelerated atherosclerosis (*Science*, 2017) and exacerbated insulin resistance (*Cell Reports*, 2020), as well as the first human genetic evidence of an association between CH and heart failure progression in the absence of atherosclerotic coronary disease in humans (JACC, 2021). Other ongoing research projects in my laboratory are related to the dissection of sex-related differences in inflammatory responses and inter-tissue communication between the adipose tissue, the hematopoietic system and the vascular wall.

PROFESSIONAL AND ACADEMIC HONORS AND RECOGNITIONS:

- 05/2018 *EAS Young Investigator Award* 2018, European Atherosclerosis Society; in recognition of the outstanding contribution to knowledge in the field of atherosclerosis and related diseases.
- 05/2018 *Irvine H. Page Young Investigator Finalist Award* 2018; American Heart Association; in recognition of the potential to become a future leader in cardiovascular research
- 06/2017 *Young Investigator Poster Award*, Gordon Research Conference on Systems-Interaction in Atherosclerosis 2017; young investigator award for outstanding poster presentation.
- 04/2017 *EAS Young Investigator Fellowship*, European Atherosclerosis Society; travel award for attendance to the European Atherosclerosis Society Congress 2017.
- 09/2014 *Junior Investigator Award*, University of Kentucky Aortic Symposium 2014; young investigator award for outstanding poster presentation.
- 03/2014 *Future of Science Travel Scholarship*, Keystone Symposia; travel award for attendance to the Keystone Symposium on Innate Immunity, Metabolism and Vascular Injury.
- 01/2010 *ESC Young Investigator Finalist Award*. European Society of Cardiology Heart Failure Winter Meeting 2010; young investigator award for outstanding poster presentation.
- 09/2005 *Spanish National Graduate Award* (Biochemistry); *Tercer Premio Nacional Fin de Carrera*
- 09/2005 *University of Valencia Extraordinary Graduate Award* (Biochemistry); *Premio Extraordinario Licenciatura*

PROFESSIONAL SOCIETIES:

- 2022-present *Member*, European Hematology Association
- 2020-present *Member*, Spanish Society of Atherosclerosis
- 2019-present *Member*, European Society of Cardiology
- 2018-present *Member*, European Association for the Study of Diabetes
- 2013-present *Member*, International Atherosclerosis Society
- 2013-present *Member*, European Atherosclerosis Society
- 2012-present *Member*, American Heart Association

OTHER ACADEMIC, PROFESSIONAL AND EDITORIAL SERVICE:

- 2024-present *Member*, PESA Study Scientific and Publications Committee, CNIC, Spain
- 2023-present *Coordinator*, Animal Facility Committee, CNIC, Spain
- 2023-present *Member*, Genomics Working Group, CNIC, Spain
- 2023-present *Member*, Bioinformatics Working Group, CNIC, Spain
- 2022-present *Member*, Coordinators Advisory Group, CNIC, Spain
- 2022-present *Coordinator*, Scientific Program on Novel Mechanisms of Atherosclerosis, CNIC, Spain

2021-present	<i>Scientific Advisory Board member</i> , U45 Japanese Section of the International Society for Heart Research (www.u45ishr.com/advisory-board/)
2021-present	<i>Adjunct Coordinator</i> , PESA Study Systems Biology Committee, CNIC, Spain
2020-2022	<i>Coordinator</i> , Frontiers in Cardiovascular Research class, Master in Molecular Biomedicine, Autonomous University of Madrid, Spain
2019-2023	<i>Guest Lecturer</i> , Inflammation in Atherosclerosis class, Master in Translational Medicine, Complutense University of Madrid, Spain.
2019-2023	<i>Coordinator</i> , Flow Cytometry Working Group, CNIC, Spain
2019-2023	<i>Member</i> , Animal Facility Committee, CNIC, Spain
2019	<i>Guest Associate Editor</i> , Frontiers in Cardiovascular Medicine – Section on Cardiovascular Metabolism
2018-present	<i>Ad-hoc Grant Reviewer</i> , European Research Council (ERC-AdG), Spanish <i>Agencia Nacional de Investigación</i> (Spain), German Federal Ministry of Education and Research (BMBF, Germany), UK Research and Innovation (UK), Science Fund of The Republic of Serbia (Serbia), National Science Center (NCN, Poland), French National Research Agency (ANR, France), Dutch Cancer Society (Netherlands), Fondazione Cariplo (Italy), Basque Government Health Department (Spain), Radiation Effects Research Foundation (RERF, Japan), Austrian Science Fund (FWF, Austria), American Heart Association (AHA, USA)
2016-present	<i>Editorial Board Member</i> , Frontiers in Cardiovascular Medicine – Section on Atherosclerosis and Vascular Medicine
2014-present	<i>Ad Hoc Reviewer</i> for the scientific journals: <i>New England Journal of Medicine</i> , <i>Science</i> , <i>European Heart Journal</i> ; <i>Journal of the American College of Cardiology</i> ; <i>Circulation</i> ; <i>JAMA Cardiology</i> , <i>Nature Cardiovascular Research</i> , <i>Science Translational Medicine</i> ; <i>Circulation Research</i> ; <i>European Journal of Heart Failure</i> ; <i>Cardiovascular Research</i> , <i>JACC: Basic to Translational Science</i> ; <i>JACC: CardioOncology</i> ; <i>Haematologica</i> ; <i>Cell Reports</i> ; <i>Cardiovascular Research</i> ; <i>EBioMedicine</i> ; <i>Cell Death & Disease</i> ; <i>Arteriosclerosis Thrombosis, and Vascular Biology</i> ; <i>Circulation: Genomics and Precision Medicine</i> ; <i>Journal of Clinical Endocrinology and Metabolism</i> ; <i>Cardiovascular Diabetology</i> ; <i>Thrombosis and Haemostasis</i> ; <i>Atherosclerosis</i> , among others.

SUPERVISION AND MENTORING ACTIVITIES

Former trainees

Vanessa Viana-Huete, PhD - Postdoctoral Associate (2018-2019)
 Nuria Matesanz, PhD – Postdoctoral Associate (2019-2023)
 M^a Carmen Asensio, PhD – Postdoctoral Associate (2021-2023)
 Marta Amorós Pérez – PhD Trainee (2019-2023)
 Alba Ferrer –M.S. Student (2019/2020)
 Asier Iturrate – M.S. Student (2019/2020)
 Clara L. Ploetner – Visiting M.S. Student (2023)
 Jelena Eric - Undergraduate Student (2019)
 Raquel García – Undergraduate Student (2021)
 Pablo Fuentes – Undergraduate Student (2022)
 Elsa Moreno – Undergraduate Student (2023)

Lorenzo Alma Marchal – Undergraduate Student (2024)

Paula García Pacheco – Undergraduate Student (2024)

Lucía Márquez Ansede – Undergraduate Student (2024)

Current postdoctoral scientists

María A. Zuriaga, PhD (since 2019)

Benedetta Izzi, PhD (since 2022)

Current predoctoral scientists

Miriam Díez (since 2020)

Beatriz López (since 2020, co-supervised by Fátima Sánchez-Cabo, CNIC)

Inés Bravo Ruíz (since 2021, co-supervised by Domingo Pascual-Figal, IMIB & CNIC)

Lucía Sánchez García (since 2024, co-supervised by Fátima Sánchez-Cabo, CNIC)

Milena di Carli (since 2024)

Eline Mol (since 2024)

Current Lab Technicians

Virginia Zorita (since 2019)

Rosa Moro (since 2019)

Diego Cuevas (since 2022)

SCIENTIFIC BIBLIOGRAPHY

ORCID  ID: [0000-0002-5970-629X](https://orcid.org/0000-0002-5970-629X)

Publons/ResearcherID: [D-3685-2011](https://publons.com/researcher/D-3685-2011)

Google Scholar: [Scholar Profile](#)

Metrics

69 scientific publications (40 as main author)

>6,541 citations, h-index: 32 (Google Scholar data); >4465 citations, h-index: 29 (WOS/JCR data)

Research Articles

* *When available, impact factor and journal impact factor rank (percentile within a specific WOS/JCR category in the year of publication or closest available) is shown for each publication.*

1. Díez-Díez M, Ramos-Neble BL, de la Barrera J, Silla-Castro JC, Quintas A, Vázquez E, Rey-Martín MA, Izzi B, Sánchez-García L, García-Lunar I, Mendieta G, Mass V, Gómez-López N, Espadas C, González G, Quesada AJ, García-Álvarez A, Fernández-Ortiz A, Lara-Pezzi E, Dopazo A, Sánchez Cabo F, Ibáñez B, Andrés V, Fuster V* and **Fuster JJ*** (2024). *Unidirectional association of clonal hematopoiesis with atherosclerosis development. **Nature Medicine** 30:2857–2866 doi: 10.1038/s41591-024-03213-1. *Co-corresponding authors*
Journal in the top 10th percentile (D1, Medicine, Research & Experimental) IF: 58.7
2. Zuriaga MA, Yu Zhi, Matesanz N, Truong B, Ramos-Neble BL, Asensio-López MC, Mesbah Uddin M, Nakao T, Niroula A, Zorita V, Amorós-Pérez M, Moro R, Ebert BL, Honigberg MC, Pascual-Figal D, Natarajan P* and **Fuster JJ*** (2024). *Colchicine prevents accelerated atherosclerosis in TET2-mutant clonal haematopoiesis. **Eur Heart J** 45:4601-4615 doi: 10.1093/eurheartj/ehae546. *Co-corresponding authors*
Journal in the top 10th percentile (D1, Cardiac & Cardiovascular Systems) IF: 38.1

3. Fuster V, García-Álvarez A, Devesa A, Mass V, Owen R, Quesada A, **Fuster JJ**, García-Lunar I, Pocock S, Sánchez-González J, Sartori S, Peyra C, Andres V, Muntendam P, and Ibanez B (2024). *Influence of subclinical atherosclerosis burden and progression on mortality. J Am Coll Cardiol* 84:1391–1403. doi:10.1016/j.jacc.2024.06.045.
Journal in the top 10th percentile (D1, Cardiac & Cardiovascular Systems) IF: 21.7
4. Iglesias-Grau J, Garcia-Alvarez A, Oliva B; Mendieta G, García-Lunar I, **Fuster JJ**, Devesa A, Pérez Herreras C, Fernández-Ortiz A, Brugada R, Ibañez B, Fernandez-Jimenez R, Fuster V (2023). *Early insulin resistance in normoglycemic low-risk individuals is associated with subclinical atherosclerosis. Cardiovascular Diabetology* 22(1):350. doi: 10.1186/s12933-023-02090-1.
Journal in the top 10th percentile (D1, Endocrinology & Metabolism) IF: 8.5
5. Mendieta G, Pocock S, Mass V, Moreno A, Owen R, García-Lunar I, López-Melgar B, **Fuster JJ**, Andres V, Pérez-Herreras C, Bueno H, Fernández-Ortiz A, Sanchez-Gonzalez J, García-Alvarez A, Ibañez B, Fuster V (2023). *Determinants of Progression and Regression of Subclinical Atherosclerosis Over 6 Years. J Am Coll Cardiol* 82:2069-2083. doi: 10.1016/j.jacc.2023.09.814.
Journal in the top 10th percentile (D1, Cardiac & Cardiovascular Systems) IF: 21.7
6. Sánchez-Cabo F, Fuster V, Silla-Castro JC, González G, Lorenzo-Vivas E, Alvarez R, Callejas S, Benguría A, Gil E, Núñez E, Oliva B, Mendiguren JM, Cortes-Canteli M, Bueno H, Andrés V, Ordovás JM, Fernández-Friera L, Quesada AJ, Garcia JM, Rossello X, Vázquez J, Dopazo A, Fernández-Ortiz A, Ibañez B, **Fuster JJ**, Lara-Pezzi E (2023). *Subclinical atherosclerosis and accelerated epigenetic age mediated by inflammation: a multi-omics study. Eur Heart J* 44(29):2698-2709. doi:10.1093/eurheartj/ehad361.
Journal in the top 10th percentile (D1, Cardiac & Cardiovascular Systems) IF: 38.1
7. Lax A, Soler F, Fernandez Del Palacio MJ, Pascual-Oliver S, Ballester MR, **Fuster JJ**, Pascual-Figal D, Asensio-Lopez MDC (2023). *Silencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55a/YY1/sST2 signaling axis. Mol Ther Nucleic Acids.* 32:704-720. doi: 10.1016/j.omtn.2023.04.031.
Journal in the top 25th percentile (Q1, Medicine, Research & Experimental) IF: 6.5
8. Seyedeh MZ, Viana-Huete V, Zuriaga MA, Md Mesbah U, Trinder M, Paruchuri K, Matesanz N, Zorita V, Ferrer-Pérez A, Amorós-Pérez M, Damrauer SM, Ballantyne CM, Gibson CJ, Pirruccello J, Griffin G, Ebert BL, Libby P, Fuster V, Zhao H, Natarajan P, Bick AG, **Fuster JJ***, Klarin D* (2023). *TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease. Nature Cardiovascular Research* 2:144–158. doi:10.1038/s44161-022-00206-6. *Co-corresponding authors. Accompanied by an *Editorial* in *Nat Cardiovasc Res.* (doi:10.1038/s44161-022-00212-8).
Journal in the top 10th percentile (D1, Cardiac & Cardiovascular Systems) IF: 9.4
9. Díez-Díez M, Amorós-Pérez M, de la Barrera J, Vázquez E, Quintas A, Pascual-Figal DA, Dopazo A, Sánchez-Cabo F, Kleinman ME, Gordon LB, Fuster V, Andrés V, **Fuster JJ** (2023). *Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome. Geroscience.* 45:1 231–1236. doi:10.1007/s11357-022-00607-2.
Journal in the top 25th percentile (Q1, Geriatrics & Gerontology) IF:5.3
10. Devesa A, Lobo-González M, Martínez-Milla J, Oliva B, García-Lunar I, Mastrangelo A, España S, Sanz J, Mendiguren JM, Bueno H, **Fuster JJ**, Andrés V, Fernández-Ortiz A, Sancho D, Fernández-Friera L, Sanchez-Gonzalez J, Rossello X, Ibanez B, Fuster V (2022). *Bone marrow activation in response to metabolic syndrome and early atherosclerosis. Eur Heart J.* 43(19):1809-1828. doi:10.1093/eurheartj/ehac102.
Journal in the top 10th percentile (D1, Cardiac and Cardiovascular Systems) IF:35.855

11. Palomo L, Santiago-Vacas E, Pascual-Figal D, **Fuster JJ**, Solé F, Bayés-Genís A (2021). *Prevalence and characteristics of clonal hematopoiesis in heart failure. Revista Espanola de Cardiologia (English ed.)*. 74(11):996-999. doi:0.1016/j.rec.2021.05.005
Journal in the top 25th percentile (Q1, Cardiac & Cardiovascular Systems) *IF: 7.062*
12. Pascual-Figal D*, Bayes-Genis A, Díez M, Hernández-Vicente A, Vázquez-Andrés D, de la Barrera J, Vazquez E, Quintas A, Zuriaga MA, Asensio-López MC, Dopazo A, Sánchez-Cabo F, **Fuster JJ*** (2021). *Clonal Hematopoiesis and Risk of Progression of Heart Failure with Reduced Left Ventricular Ejection Fraction. J. Am. Coll. Cardiol.* 77(14):1747-1759. doi:10.1016/j.jacc.2021.02.028. ***Co-corresponding authors.**
Journal in the top 10th percentile (D1, Cardiac and Cardiovascular Systems) *IF: 27.206*
Accompanied by an *Editorial* in *J. Am. Coll. Cardiol.* (doi:10.1016/j.jacc.2021.02.045).
13. **Fuster JJ***, Zuriaga MA, Zorita V, MacLauchlan S, Polackal MN, Viana-Huete V, Ferrer-Pérez A, Matesanz N, Herrero-Cervera A, Sano S, Cooper MA, González-Navarro H, Walsh K* (2020). *TET2 loss of function-driven clonal hematopoiesis exacerbates experimental insulin resistance in aging and obesity. Cell Reports.* 33(4):108326. doi:10.1016/j.celrep.2020.108326. ***Co-corresponding authors.**
Journal in the top 25th percentile (Q1, Cell Biology) *IF: 9.423*
14. Wang Y, Sano S, Yura Y, Ke Z, Sano M, Oshima K, Ogawa H, Horitani K, Min KD, Miura-Yura E, Kour A, Evans MA, Zuriaga MA, Hirschi KK, **Fuster JJ**, Pietras EM, Walsh K (2020). *Tet2-mediated clonal hematopoiesis in nonconditioned mice accelerates age-associated cardiac dysfunction. JCI Insight.*;5(6): e135204. doi:10.1172/jci.insight.135204.
Journal in the top 25th percentile (Q1, Medicine, Research & Experimental) *IF: 8.315*
15. Sano S, Oshima K, Wang Y, MacLauchlan S, Katanasaka Y, Sano M, Zuriaga MA, Yoshiyama M, Goukassian D, Cooper MA, **Fuster JJ**, Walsh K (2018). *Tet2-mediated clonal hematopoiesis accelerates experimental heart failure through an IL-1 β /NLRP3 inflammasome mechanism. J. Am. Coll. Cardiol.* 71(8):875-886. doi:10.1016/j.jacc.2017.12.037.
Journal in the top 10th percentile (D1, Cardiac and Cardiovascular Systems) *IF: 18.639*
Accompanied by: *Editorial* in *J. Am. Coll. Cardiol.* (doi:10.1016/j.jacc.2017.12.038); *Research Highlight* in *Nature Reviews Cardiology* (doi:10.1038/nrcardio.2018.22); *Editor's Choice* in *Science Translational Medicine* (doi:10.1126/scitranslmed.aat3885).
16. Molina-Sánchez P, Del Campo L, Esteban V, Rius C, Chèvre R, **Fuster JJ**, Ferrer M, Redondo JM, Andres V (2018). *Defective p27 phosphorylation at serine 10 affects vascular reactivity and increases abdominal aortic aneurysm development via Cox-2 activation. J. Mol. Cell. Cardiol.* 116:5-15. doi:10.1016/j.yjmcc.2018.01.010.
Journal in the top 25th percentile (Q1, Cardiac and Cardiovascular Systems) *IF: 5.055*
17. Zuriaga MA, **Fuster JJ**, Farb MG, MacLauchlan S, Bretón-Romero R, Karki S, Hess DT, Apovian CM, Hamburg NM, Gokce N, Walsh K (2017). *Activation of non-canonical WNT signaling in human visceral adipose tissue contributes to local and systemic inflammation. Scientific Reports.* 11;7(1):17326. doi:10.1038/s41598-017-17509-5. PMID: 29229927
Journal in the top 25th percentile (Q1, Multidisciplinary Sciences) *IF: 4.122*
18. **Fuster JJ***, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R, Wu C-L, Sano S, Muralidharan S, Rius C, Vuong J, Jacob S, Muralidhar V, Robertson AAB, Cooper MA, Andres V, Hirschi KK, Martin KA, Walsh K* (2017). *Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science.* 355(6327):842-847. doi:10.1126/science.aag1381. ***Co-corresponding authors**
Journal in the top 10th percentile (D1, Multidisciplinary Sciences) *IF: 41.058*

Editorials and Research Highlight articles on *Fuster et al, Science 2017*:

Perspective: Hematopoietic stem cells gone rogue. Zhu YP, Hedrick CC, Gaddis DE. *Science*. 2017 Feb 24;355(6327):798-799. doi:10.1126/science.aam7939.

News and Views: Cardiovascular disease: Commonality with cancer. Tall AR, Levine RL. *Nature*. 2017 Mar 2;543(7643):45-47. doi:10.1038/nature21505

Research Highlight: *Nature*. 2017 Jan 25; 541:438. doi:10.1038/541438c.

Research Highlight: *Nature Reviews Drug Discovery*. 2017 Mar 1;16(3):166. doi:10.1038/nrd.2017.40.

Research Highlight: *Nature Immunology*. 2017 Mar 22;18(4):373. doi:10.1038/ni.3721.

Editor's choice: *Science Signaling*. 2017 Feb 28;10(468). doi:10.1126/scisignal.aan0468.

Selected by *Nature Medicine* as *Notable Biomedical Advance of the Year 2017*.

Nature Medicine 2017;23:1387. doi:10.1038/nm1217-1387.

Recommended in *F1000prime*: <https://f1000.com/prime/727224345>

19. MacLauchlan S, Zuriaga MA, **Fuster JJ**, Cuda C, Jonason J, Behzadi F, Parker Duffen J, Haines III GK, Aprahamian T, Perlman H, Walsh K (2017). *Genetic deficiency of *Wnt5a* diminishes disease severity in a murine model of rheumatoid arthritis. **Arthritis Res Ther**. 19(1):166. doi:10.1186/s13075-017-1375-0.*

Journal in the top 25th percentile (Q1, Rheumatology) *IF: 4.269*

20. Zuriaga MA, **Fuster JJ**, Gokce N, Walsh K (2017). *Humans and Mice Display Opposing Patterns of "Browning" Gene Expression in Visceral and Subcutaneous White Adipose Tissue Depots. **Front Cardiovasc Med**. 4:27. doi:10.3389/fcvm.2017.00027.*

Journal in the top 50th percentile (Q2, Cardiac & Cardiovascular Systems) *IF: 3.915*

21. Bretón-Romero R, Feng B, Holbrook M, Farb MG, Fetterman JL, Linder EA, Berk BD, Masaki N, Weisbrod RM, Inagaki E, Gokce N, **Fuster JJ**, Walsh K, Hamburg NM (2016). *Endothelial Dysfunction in Human Diabetes Is Mediated by *Wnt5a*-JNK Signaling. **Arterioscler Thromb Vasc Biol**. 36(3):561-9. doi:10.1161/ATVBAHA.115.306578*

Journal in the top 10th percentile (D1, Peripheral Vascular Disease) *IF: 6.607*

22. Farb MG, Karki S, Park SY, Saggese SM, Carmine B, Hess DT, Apovian C, Fetterman JL, Bretón-Romero R, Hamburg NM, **Fuster JJ**, Zuriaga MA, Walsh K, Gokce N (2016). *WNT5A-JNK regulation of vascular insulin resistance in human obesity. **Vascular Medicine**. 21(6):489-496. doi:10.1177/1358863X16666693.*

Journal in the top 75th percentile (Q3, Peripheral Vascular Disease) *IF: 1.866*

23. Nakamura K, Sano S, **Fuster JJ**, Kikuchi R, Shimizu I, Ohshima K, Katanasaka Y, Ouchi N, Walsh K (2016). *Secreted Frizzled-related Protein 5 Diminishes Cardiac Inflammation and Protects the Heart from Ischemia/Reperfusion Injury. **J Biol Chem**. 291(6):2566-75. doi:10.1074/jbc.M115.693937.*

Journal in the top 50th percentile (Q2, Biochemistry & Molecular Biology) *IF: 4.125*

24. Valero-Muñoz M, Li S, Wilson RM, Hulsmans M, Aprahamian T, **Fuster JJ**, Nahrendorf M, Scherer PE, Sam F (2016). *Heart Failure With Preserved Ejection Fraction Induces Beiging in Adipose Tissue. **Circ Heart Fail**. 9(1):e002724. doi:10.1161/CIRCHEARTFAILURE.115.002724.*

Journal in the top 25th percentile (Q1, Cardiac & Cardiovascular Systems) *IF: 6.372*

25. Molina-Sánchez P, Chèvre R, Rius C, **Fuster JJ**, Andrés V (2015). *Loss of p27 phosphorylation at Ser10 accelerates early atherogenesis by promoting leukocyte recruitment via RhoA/ROCK.* **J Mol Cell Cardiol.** 84:84-94. doi:10.1016/j.yjmcc.2015.04.013.
Journal in the top 25th percentile (Q1, Cardiac & Cardiovascular Systems) *IF: 4.784*
26. **Fuster JJ**, Zuriaga MA, Ngo DT, Farb MG, Aprahamian T, Yamaguchi TP, Gokce N, Walsh K (2015). *Non-canonical Wnt signaling promotes obesity-induced adipose tissue inflammation and metabolic dysfunction.* **Diabetes.** 64(4):1235-48. doi:10.2337/db14-1164.
Journal in the top 10th percentile (D1, Endocrinology & Metabolism) *IF: 8.784*
27. Kikuchi R, Nakamura K, MacLauchlan S, Ngo DT, Shimizu I, **Fuster JJ**, Katanasaka Y, Yoshida S, Qiu Y, Yamaguchi TP, Matsushita T, Murohara T, Gokce N, Bates DO, Hamburg NM, Walsh K (2014). *An antiangiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease.* **Nat Med.** 20:1464-71. doi:10.1038/nm.3703.
Journal in the top 10th percentile (D1, Medicine, Research and Experimental) *IF: 28.223*
28. Yoshida S, **Fuster JJ**, Walsh K (2014). *Adiponectin attenuates abdominal aortic aneurysm formation in hyperlipidemic mice.* **Atherosclerosis.** 235(2):339-346. doi:10.1016/j.atherosclerosis.2014.05.923.
Journal in the top 25th percentile (Q1, Peripheral Vascular Disease) *IF: 3.994*
29. Murdoch CE, Shuler M, Haeussler DJF, Kikuchi R, Bearely P, Han J, Watanabe Y, **Fuster JJ**, Walsh K, Ho YS, Bachschmid MM, Cohen RA, Matsui R (2014). *Glutaredoxin-1 up-regulation induces soluble vascular endothelial growth factor receptor 1, attenuating post-ischemia limb revascularization.* **J Biol Chem.** 289:8633-8644. doi:10.1074/jbc.M113.517219.
Journal in the top 25th percentile (Q1, Biochemistry & Molecular Biology) *IF: 4.573*
30. Zotes TM, Arias CF, **Fuster JJ**, Spada R, Pérez-Yagüe S, Hirsch E, Wymann M, Carrera AC, Andrés V, Barber DF (2013). *PI3K p110 γ deletion attenuates murine atherosclerosis by reducing macrophage proliferation but not polarization or apoptosis in lesions.* **PLoS One.** 8(8):e72674. doi: 10.1371/journal.pone.0072674
Journal in the top 25th percentile (Q1, Multidisciplinary Sciences) *IF: 3.534*
31. **Fuster JJ**, Molina-Sánchez P, Jovaní D, Vinué Á, Serrano M, Andrés V (2012). *Increased gene dosage of the Ink4/Arf locus does not attenuate atherosclerosis development in hypercholesterolaemic mice.* **Atherosclerosis.** 221:98-105. doi:10.1016/j.atherosclerosis.2011.12.013.
Journal in the top 25th percentile (Q1, Peripheral Vascular Disease) *IF: 3.706*
32. **Fuster JJ**, González-Navarro H, Vinué A, Molina-Sánchez P, Andrés-Manzano MJ, Nakayama KI, Nakayama K, Díez-Juan A, Bernad A, Rodríguez C, Martínez-González J, Andrés V (2011). *Deficient p27 phosphorylation at serine 10 increases macrophage foam cell formation and aggravates atherosclerosis through a proliferation-independent mechanism.* **Arterioscler Thromb Vasc Biol.** 31:2455-2463 doi:10.1161/ATVBAHA.111.235580.
Journal in the top 10th percentile (D1, Peripheral Vascular Disease) *IF: 6.368*
33. **Fuster JJ**, González JM, Edo MD, Viana R, Boya P, Cervera J, Verges M, Rivera J, Andrés V (2010). *Tumor suppressor p27(Kip1) undergoes endolysosomal degradation through its interaction with sorting nexin 6.* **FASEB J.** 24:2998-3009. doi:10.1096/fj.09-138255.
Journal in the top 10th percentile (D1, Biology) *IF: 6.515*

34. Sanz-González SM, Barquín L, García-Cao I, Roque M, González JM, **Fuster JJ**, Castells MT, Flores JM, Serrano M, Andrés V (2007). *Increased p53 gene dosage reduces neointimal thickening induced by mechanical injury but has no effect on native atherosclerosis. **Cardiovasc Res.** 75:803-812. doi:10.1016/j.cardiores.2007.05.002.*

Journal in the top 10th percentile (D1, Cardiac & Cardiovascular Systems) IF: 6.127

35. Fernández-Medarde A, Porteros A, de las Rivas J, Núñez A, **Fuster JJ**, Santos E (2007). *Laser microdissection and microarray analysis of the hippocampus of Ras-GRF1 knockout mice reveals gene expression changes affecting signal transduction pathways related to memory and learning. **Neuroscience.** 146:272-85. doi:10.1016/j.neuroscience.2007.01.022.*

Journal in the top 50th percentile (Q2, Neurosciences) IF: 3.352

Invited Reviews and Editorials

36. Verdonschot JAJ, **Fuster JJ**, Walsh K and Heymans SRB (2024). *The emerging role of clonal haematopoiesis in the pathogenesis of dilated cardiomyopathy. **Eur Heart J** 45:4797-4807 doi: 10.1093/eurheartj/ehae682.*

Journal in the top 10th percentile (D1, Cardiac & Cardiovascular Systems) IF: 38.1

37. Nielsen RV, Fuster V, Bundgaard H, **Fuster JJ**, Johri AM, Kofoed KF, Douglas PS, Diederichsen A, Shapiro MD, Nicholls SJ, Nordestgaard BG, Lindholt JS, MacRae C, Yuan C, Newby DE, Urbina, EM, Bergström G, Ridderstråle M, Budoff MJ, Bøttcher M, Raitakari OT, Hansen TH, Näslund U, Sillesen H, Eldrup N, and Ibanez B (2024). *Personalized Intervention Based on Early Detection of Atherosclerosis: JACC State-of-the-Art Review. **J Am Coll Cardiol** 83:2112-2127 doi:10.1016/j.jacc.2024.02.053.*

Journal in the top 10th percentile (D1, Cardiac & Cardiovascular Systems) IF: 21.7

38. Zuriaga A, Pascual-Figal D, **Fuster JJ** (2023). *Clonal hematopoiesis and cardiac arrhythmias: rhythm-altering mutations. **European Heart Journal.** 45:806-808. doi:10.1093/eurheartj/ehae052.*

Journal in the top 10th percentile (D1, Cardiac & Cardiovascular Systems) IF: 38.1

39. **Fuster JJ** (2023). *Clonal hematopoiesis and coronary artery disease: a deep connection. **JAMA Cardiology.** 9:242-244. doi:10.1001/jamacardio.2023.5106*

Journal in the top 10th percentile (D1, Cardiac & Cardiovascular Systems) IF: 14.4

40. Izzi B and **Fuster JJ** (2023). *Clonal Hematopoiesis And Cardiovascular Risk: Atherosclerosis, Thrombosis And Beyond. **Hämostaseologie.** 44:013-020. doi:10.1055/a-2219-6410*

Journal in the top 50th percentile (Q2, Hematology) IF: 2.7

41. Pascual-Figal D, **Fuster JJ**, Bayés-Genís (2023). *Personalizing anti-inflammatory therapy in heart failure: A new way. **Eur J Heart Fail.** 25(11):1933-1935. doi: 10.1002/ejhf.3052.*

Journal in the top 10th percentile (D1, Cardiac & Cardiovascular Systems) IF: 16.9

42. Salloum FN, Tocchetti CG...Fuster JJ... Ky B, López-Fernández T (2023). *Priorities in Cardio-Oncology Basic and Translational Science: GCOS 2023 Symposium Proceedings. **JACC CardioOncol.** 5(6):715-731. doi: 10.1016/j.jacc.2023.08.003.*

Journal in the top 10th percentile (D1, Cardiac & Cardiovascular Systems) IF: 13.6

43. **Fuster JJ** and Izzi B (2023). *Clonal Hematopoiesis in Patients With Atherosclerotic Cardiovascular Disease: One Step Closer to the Clinical Scenario. **J Am Coll Cardiol.** 81(20):2010-2012. doi:10.1016/j.jacc.2023.03.420.*

Journal in the top 10th percentile (D1, Cardiac & Cardiovascular Systems) IF: 21.7

44. Zuriaga MA and **Fuster JJ** (2023). *New insights into the dynamics of age-related clonal hematopoiesis. Journal of Cardiovascular Aging.* 3:2. doi: 10.20517/jca.2022.38.
IF: not yet available
45. Zuriaga MA and **Fuster JJ** (2023). *Clonal hematopoiesis and atherosclerotic cardiovascular disease: A primer. Clínica e Investigación en Arteriosclerosis.* 35:5-41. doi:10.1016/j.arteri.2021.09.006.
Journal in the top 75th percentile (32, Peripheral Vascular Disease) IF: 1.9
46. Zuriaga MA and **Fuster JJ** (2023). *Emerging Role of Acquired Mutations and Clonal Hematopoiesis in Atherosclerosis—Beyond Conventional Cardiovascular Risk Factors—. Circulation Journal.* 87:394-400. doi:10.1253/circj.CJ-21-0505
Journal in the top 50th percentile (Q2, Cardiac & Cardiovascular Systems) IF: 3.1
47. Tall A* and **Fuster JJ*** (2022). *Clonal Hematopoiesis In Cardiovascular Disease And Therapeutic Implications. Nature Cardiovascular Research.* 1:116-124. doi:10.1038/s44161-021-00015-3
 *Co-corresponding authors.
Journal in the top 10th percentile (D1, Cardiac & Cardiovascular Systems) IF: 9.4
48. Díez-Díez M, **Fuster JJ** (2022). *Troublemaking mutations: Clonal hematopoiesis for the prediction of prognosis in ST-segment elevation myocardial infarction. EBioMedicine.* 79:104015. doi: 10.1016/j.ebiom.2022.104015.
Journal in the top 10th percentile (D1, Medicine, Research & Experimental) IF: 11.205
49. **Fuster JJ** (2022). *Clonal Hematopoiesis and Cardiovascular Disease in Cancer Patients and Survivors. Thrombosis Research.* ;213 Suppl 1:S107-S112 doi:10.1016/j.thromres.2021.12.009.
Journal in the top 10th percentile (D1, Peripheral Vascular Disease) IF: 10.409
50. Sánchez-Cabo and **Fuster JJ** (2021). *Clonal haematopoiesis and atherosclerosis: a chicken or egg question? Nature Reviews Cardiology* 18:463-464. doi:10.1038/s41569.021.00554.z
Journal in the top 10th percentile (D1, Cardiac & Cardiovascular Systems) IF: 49.421
51. **Fuster JJ** (2021). *Clonal Hematopoiesis and Incident Heart Failure Risk: The Clone Wars Reach the Myocardium. J. Am. Coll. Cardiol.* 78 (1), 53-55 doi:10.1016/j.jacc.2021.04.084
Journal in the top 10th percentile (D1, Cardiac & Cardiovascular Systems) IF: 27.206
52. Amorós-Pérez M & **Fuster JJ** (2020). *Clonal hematopoiesis driven by somatic mutations: A new player in atherosclerotic cardiovascular disease. Atherosclerosis.* 297:120-126. doi:10.1016/j.atherosclerosis.2020.02.008
Journal in the top 25th percentile (Q1, Peripheral Vascular Disease) IF: 5.162
53. Khetarpal SA, Qamar A, Bick AG, **Fuster JJ**, Kathiresan S, Jaiswal S and Natarajan P (2019). *Clonal Hematopoiesis of Indeterminate Potential Reshapes Age-Related CVD. J Am Coll Cardiol.* 74 (4), 578-586. doi:10.1016/j.jacc.2019.05.045. PMID: 31345433
Journal in the top 10th percentile (D1, Cardiac & Cardiovascular Systems) IF: 20.589
54. Viana-Huete V and **Fuster JJ** (2019). *Potential therapeutic value of interleukin 1 β -targeted strategies in atherosclerotic cardiovascular disease. Rev Esp Cardiol.* 72 (9), 760-766. doi:10.1016/j.rec.2019.03.006.
Journal in the top 25th percentile (Q1, Cardiac & Cardiovascular Systems) IF: 4.642

55. **Fuster JJ** (2019). *Integrated Stress Response Inhibition in Atherosclerosis: Preventing the Stressed-Out Plaque. J Am Coll Cardiol.* 73(10):1170-1172. doi:10.1016/j.jacc.2019.01.015.
Journal in the top 10th percentile (D1, Cardiac & Cardiovascular Systems) IF: 20.589
56. **Fuster JJ** (2018). *TLR4 in Atherogenesis: Paying the Toll for Antimicrobial Defense. J Am Coll Cardiol.* 10;71(14):1571-1573. doi:10.1016/j.jacc.2018.02.014.
Journal in the top 10th percentile (D1, Cardiac & Cardiovascular Systems) IF: 18.639
57. **Fuster JJ*** and Walsh K* (2018). Somatic *mutations* and clonal hematopoiesis: unexpected potential new drivers of age-related cardiovascular disease. *Circ Res.* 122(3):523-532. doi:10.1161/CIRCRESAHA.117.312115. *Co-corresponding authors.
Journal in the top 10th percentile (D1, Cardiac & Cardiovascular Systems) IF: 15.862
58. **Fuster JJ***, Ouchi N, Gokce N, Walsh K* (2016). *Obesity-Induced Changes in Adipose Tissue Microenvironment and Their Impact on Cardiovascular Disease. Circ Res.* 118(11):1786-807. doi:10.1161/CIRCRESAHA.115.306885. *Co-corresponding authors
Journal in the top 10th percentile (D1, Cardiac & Cardiovascular Systems) IF: 13.965
59. **Fuster JJ**, Walsh K (2014). *The good, the bad and the ugly of interleukin 6 signaling. EMBO J.* 33:1425-1427. doi:10.15252/embj.201488856.
Journal in the top 10th percentile (D1, Cell Biology) IF: 10.434
60. Nakamura K, **Fuster JJ**, Walsh K (2014). *Adipokines: A link between obesity and cardiovascular disease. J Cardiol.* 63:250-259. doi:10.1016/j.jjcc.2013.11.006.
Journal in the top 50th percentile (Q2, Cardiac & Cardiovascular Systems) IF: 2.782
61. **Fuster JJ**, Fernández P, González-Navarro H, Silvestre C, Nabah YN, Andrés V (2010). *Control of cell proliferation in atherosclerosis: insights from animal models and human studies. Cardiovasc Res.* 86:254-264. doi:10.1093/cvr/cvp363.
Journal in the top 10th percentile (D1, Cardiac & Cardiovascular Systems) IF: 6.051
62. **Fuster JJ**, Andrés V (2010). *A role for miR-33 in p53 regulation: New perspectives for hematopoietic stem cell research. Cell Cycle.* 9(17):3397-8. doi:10.4161/cc.9.17.13070.
Journal in the top 50th percentile (Q2, Cell Biology) IF: 4,999
63. **Fuster JJ**, Díez J, Andrés V (2007). *Telomere dysfunction in hypertension. J Hypertens.* 25:2185-2192. doi:10.1097/HJH.0b013e3282ef6196.
Journal in the top 25th percentile (Q1, Peripheral Vascular Disease) IF: 4,364
64. **Fuster JJ**, Sanz-González SM, Moll UM, Andrés V (2007). *Classic and novel roles of p53: prospects for anticancer therapy. Trend Mol Med* 13:192-199 doi:10.1016/j.molmed.2007.03.002.
Journal in the top 10th percentile (D1, Medicine, Research & Experimental) IF 7,244
65. **Fuster JJ**, Andrés V (2006). *Telomere biology and cardiovascular disease. Circ Res.* 99:1167-1180. doi:10.1161/01.RES.0000251281.00845.18.
Journal in the top 10th percentile (D1, Cardiac & Cardiovascular Systems) IF: 9.854

Book Chapters

66. **Fuster JJ**, Zuriaga MA and Fuster V (2023). Inflammation as a driver of disease. **Encyclopedia of Cell Biology**. 2nd Edition, edited by Ralph A. Bradshaw, Gerald W. Hart, and Philip D Stahl. ISBN: 978-0-12-821624-8

67. **Fuster JJ** (2015). "*Quantification of cellular proliferation in mouse atherosclerotic lesions*" in "Methods in Mouse Atherosclerosis" of the series "Methods in Molecular Biology" (Elsevier 2015). *Methods Mol Biol.* 1339:201-10. PMID: 26445791
68. **Fuster JJ**, Castillo AI, Zaragoza C, Ibáñez B, Andrés V (2014). "*Animal models of atherosclerosis*" in Progress in Molecular Biology and Translational Science - Animal Models of Molecular Pathology (Elsevier 2014). *Prog Mol Biol Transl Sci.*105:1-23. PMID: 22137427
69. **Andrés V**, **Fuster JJ**, Silvestre-Roig C, Wessely R (2012). "*Modulating the Proliferative Response to Treat Restenosis after Vascular Injury*" in Molecular and Translational Vascular Medicine (Springer 2012). *Mol Transl Vasc Med.* 227-248

ACTIVE RESEARCH SUPPORT

1. *A Blueprint of Inflammatory Drivers of Heart Failure with Preserved Ejection Fraction (ID-PRESERVED)*. **EU ERA4HEALTH – CARDINNOV Call**. P.I. and international consortium coordinator: José J. Fuster. Period: 01/01/2024-31/12/2026.
2. *Precision biomarkers to improve the diagnosis and treatment of inflammatory myocardial disease (PreMYO)*. **Personalized Medicine Projects Call – Instituto de Salud Carlos III (ISCIII)**. P.I.: Domingo Pascual-Figal. WP5 project leader: José J. Fuster. Period: 01/01/2023-31/12/2025.
3. *Somatic mutations and clonal hematopoiesis as predictors and drivers of heart failure progression (MyoClonal)*. **La Caixa banking foundation**. P.I. and national consortium coordinator. José J. Fuster. Period: 01.10.2022-31.09.2025
4. *Mosaic Loss of Y Chromosome in blood and accelerated atherosclerosis development (CLONAL-Y)*. **Ministerio de Ciencia e Innovación**. P.I.: José J. Fuster. Period: 01/09/2022-31/08/2025.
5. *Somatic mutations and clonal hematopoiesis as drivers of atherosclerosis: from the laboratory to the clinic (AtheroClonal)*. **Ministerio de Ciencia e Innovación**. P.I. and National Consortium Coordinator: José J. Fuster. Period: 15/12/2021-14/12/2024

PAST RESEARCH SUPPORT

1. *Transatlantic Leducq Network on Clonal Hematopoiesis and Atherosclerosis*. **Leducq Foundation**. Network Member: José J. Fuster. Period: 01.01.2020-31.12.2023.
2. *Case-Control Study – Identifying New Prognostic Biomarkers Predictive of Exacerbated Subclinical Atherosclerosis*. **Novo Nordisk Foundation**. P.I.: José J. Fuster. Period: 01/08/2023-31/12/2023.
3. *Cancer Therapy-Related Clonal Hematopoiesis as a Driver of Accelerated Atherosclerosis (CHEMICAL consortium)*. **Instituto de Salud Carlos III / European Research Area Network on Cardiovascular Diseases (ERA-CVD)**. P.I. and International Consortium Coordinator: José J. Fuster. Period: 01.01.2020-31.12.2023.
4. *Ramón y Cajal Award Grant*. **Ministry of Science and Innovation**. PI: José J. Fuster. Period: 01.09.2018-31.08.2023.
5. *Hematopoyesis Clonal Inducida Por Mutaciones Somáticas en Tet2 En La Progresión De La Aterosclerosis*. **Ministerio de Ciencia, Innovación y Universidades. Programa estatal de I+D+I «Retos Investigación»**. P.I.: José J. Fuster. Period: 01.01.2019-31.08.2022
6. *Mutaciones adquiridas en células sanguíneas y hematopoyesis clonal: un posible nuevo mecanismo patogénico de enfermedad cardiovascular aterosclerótica*. **CIBER-CV (Intramural Research call)**. Co-PI: José J. Fuster. Period: 01.01.2021-30.06.2022.

7. *Mutaciones somáticas y hematopoyesis clonal en enfermedad cardiovascular aterosclerótica*. **BBVA Foundation - Leonardo Grant for Researchers and Cultural Creators**. P.I José J. Fuster. Period: 01.10.2019-31.03.2021.
8. *Somatic Mutation-driven Clonal Hematopoiesis in Atherosclerosis - International Consortium*. **La Caixa banking foundation**. P.I. Valentín Fuster / Co-Project Leader: José J Fuster. Period: 1.1.2019-31.08.2022
9. *TET2 loss of function-induced clonal hematopoiesis: a new driver of insulin resistance*. **EFSD/Lilly European Diabetes Research Programme #97015. European Foundation for the Study of Diabetes (EFSD)**. P.I José J. Fuster. Period: 01.04.2019-31.03.2020
10. *Somatic TET2 mutation-driven clonal hematopoiesis in atherosclerosis*. **USA National Institutes of Health (NIH-NHLBI)** NIH R01 HL141123-1 P.I José J. Fuster. Period: 01.04.2018-31.12.2023 (award relinquished on 31.08.2018 upon acceptance of a position outside the USA)
11. *Role of age-associated TET2 mutations in atherosclerosis*. **American Heart Association (AHA) Scientist Development Grant 17SDG33400213** P.I José J. Fuster. Period: 01.01.2017-31.12.2019 (award relinquished on 31.08.2018 upon acceptance of a position outside the USA)

INVITED LECTURES AND PRESENTATIONS (selection from 2019-present)

- 11/2024 “Clonal hematopoiesis and cardiovascular disease: from humans to mice and back” European Vascular Biology Organization Seminar Series [*Invited Online Lecture*]
- 11/2024 “Clonal hematopoiesis and cardiovascular disease: from humans to mice and back” Instituto de Investigaciones Biomédicas Sols-Morreale CSIC/UAM, Madrid, Spain [*Invited Lecture*]
- 10/2024 “Hematopoyesis clonal, enfermedad cardiovascular y thrombosis”. 2024 National Congress *Sociedad Española de Hematología y Hematoterapia (SEHH)*. Palma de Malloca, Spain [*Invited Lecture*]
- 09/2024 “Clonal haematopoiesis and atherosclerotic disease – from humans to mice and back”. 29th Kraków Conference on Endothelium. Kraków, Poland [*Invited Keynote Lecture*]
- 09/2024 “Mutaciones somáticas, hematopoyesis clonal y enfermedad aterosclerótica”. XXVIII Congreso Nacional de Geriatria y Gerontología, Chile [*Invited Online Lecture*]
- 08/2024 “Clonal haematopoiesis and cardiovascular diseases” European Society of Cardiology Congress 2024. London, UK [*Invited Lecture*]
- 07/2024 “Clonal hematopoiesis of indeterminate potential and the risk of cardiovascular diseases” French Society of Cardiology Printemps de la Cardiologie 2024 Conference. Lille, France [*Invited Plenary Lecture*]
- 06/2024 “CHIPs can be dangerous for your heart: The impact of aging and cardiovascular diseases” 29th European Hematology Association (EHA) Congress, Madrid, Spain [*Invited Lecture*]
- 03/2024 “Clonal hematopoiesis and cardiovascular disease: from humans to mice and back” Center for Population Health Innovation (POINT) University Heart & Vascular Center. Hamburg, Germany [*Invited Online Lecture*]
- 02/2024 “Clonal hematopoiesis and cardiovascular disease: from humans to mice and back” GTH 2024 - 68th Annual Meeting of the Society of Thrombosis and Haemostasis research. Vienna, Austria [*Invited Plenary Lecture*]

- 02/2024 “Clonal hematopoiesis and cardiovascular disease: from humans to mice and back” Belgian Society of Cardiology Congress 2024. Brussels, Belgium [*Invited Lecture*]
- 12/2023 “Clonal Hematopoiesis: a new perspective in population health”. Towards Comprehensive Population Studies II conference. Bialystok, Poland [*Invited Lecture*]
- 11/2023 “Clonal Hematopoiesis: the Clone Wars in Cardiovascular Disease”. Karolinska Institute Cardiovascular Research Program Scientific Retreat 2023. Stockholm, Sweden. [*Invited Lecture*]
- 11/2023 “Intersections Between Cardiovascular Biology and Cancer: CHIP and Beyond” American Heart Association Scientific Sessions 2023. Philadelphia, PA, USA. [*Invited Lecture*]
- 09/2023 “Clonal hematopoiesis, cancer and cardiovascular diseases”. Global Cardio Oncology Summit 2023 – Basic and Translational Research Symposium. Madrid, Spain. [*Invited Lecture*]
- 08/2023 “CHIP - a novel risk factor atherosclerotic CVD”. Atherosclerosis: Molecular Mechanisms, Genomic Modifiers and Therapeutic Strategies - Danish Cardiovascular Academy. Korsør, Denmark. [*Invited Lecture*].
- 06/2023 “Hematopoyesis clonal de potencial indeterminado”. XXXV Annual Meeting – Spanish Society of Atherosclerosis (SEA). A Coruña, Spain. [*Invited Lecture*].
- 05/2023 “Clonal hematopoiesis: hematopoietic clone wars in the cardiovascular system”. Mount Sinai Cardiovascular Research Institute. New York, USA. [*Invited Lecture*].
- 05/2023 “Hematopoyesis Clonal y Enfermedad Cardiovascular”. VII GEMFIN Annual Meeting. Madrid, Spain. [*Invited Lecture*]
- 03/2023 “Perspectivas de futuro en el tratamiento de enfermedades cardiovasculares”. XIII XIII Pharmaceutical Science Students Congress. University of Valencia, Valencia, Spain. [*Invited Lecture*]
- 01/2023 “Somatic mutations and clonal hematopoiesis in cardiovascular and metabolic disease”. IMDEA Research Institute on Food and Health Sciences. Madrid, Spain. [*Invited Lecture*]
- 01/2023 “Clonal Hematopoiesis and Cardiovascular Disease at CNIC, Madrid, Spain”. ImPRESS PhD Program Final Conference. Medical University of Bialystok, Poland. [*Invited Online Lecture*]
- 09/2022 “Cancer Therapy-Related Clonal Hematopoiesis as a Driver of Accelerated Atherosclerosis” ERA-Net on Cardiovascular Diseases (ERA-CVD) Symposium 2022, Riga (Latvia) [*Invited Lecture*]
- 09/2022 “Hematopoyesis clonal de significado incierto y enfermedad cardiovascular”. XV Congreso Argentino de Hemostasia y Trombosis 2022, Buenos Aires (Argentina) [*Invited Lecture*]
- 07/2022 “Clonal hematopoiesis: hematopoietic clone wars in the cardiovascular system” American Heart Association Basic Cardiovascular Science Scientific Sessions 2022, Chicago (USA) [*Invited Lecture*]
- 06/2022 “Clonal hematopoiesis and atherosclerosis: hematopoietic clone wars in the arterial wall” DZHK Science on Friday, German Centre for Cardiovascular Research: DZHK, Germany [*Invited Online Lecture*]
- 05/2022 “Clonal hematopoiesis affecting cardiovascular health”. 90th EAS Congress, European Atherosclerosis Society, Milan (Italy) [*Invited Lecture*]

- 05/2022 “Clonal hematopoiesis and cardiovascular complications in cancer patients and survivors” 11th International Conference on Thrombosis & Hemostasis Issues in Cancer (ICTHIC 2022), Bergamo (Italy) [*Invited Lecture*]
- 04/2022 “Clonal hematopoiesis and cardiovascular disease”. University of Glasgow, Scotland [*Invited Online Lecture*]
- 12/2021 “Acquired Mutations and Clonal Hematopoiesis: the Clone Wars in Cardiovascular Disease”. SBM Department Annual Conference - Université de Bordeaux, France [*Invited Keynote Lecture*]
- 10/2021 “Age-Related Mutations and Clonal Hematopoiesis In Atherosclerosis: Beyond Conventional Cardiovascular Risk Factors”. 18th International Symposium on Atherosclerosis, International Atherosclerosis Society, Kyoto, Japan [*Invited Lecture*]
- 09/2021 “Somatic mutations and clonal hematopoiesis in atherosclerotic cardiovascular disease”. Cardiovascular Network Symposium 2021. Aarhus University, Denmark [*Invited Lecture*]
- 06/2021 “Thematic Debate: Clonal Hematopoiesis and Cardiovascular Disease”. European Hematology Association Virtual Congress 2021. [*Invited Online Lecture*]
- 06/2021 “Clonal Hematopoiesis – Links to Atherosclerotic Disease”. British Cardiovascular Society Annual Conference 2021 - BAS/BSCR Joint Online Spring Meeting Online. [*Invited Online Lecture*]
- 03/2021 “Somatic mutations and clonal hematopoiesis in atherosclerosis and beyond”. Harvard Medical School & Brigham and Women’s Hospital Vascular Biology Seminars, Boston, MA, USA [*Invited Online Lecture*]
- 02/2021 “Mutaciones adquiridas: un nuevo factor de riesgo en patología cardiovascular”. 16^a Reunión Internacional sobre Investigación Traslacional y Medicina de Precisión - Bases Genéticas de Enfermedades Comunes. Fundación Instituto Roche/Fundación Jiménez Díaz Hospital. Madrid, Spain. [*Invited Online Lecture*]
- 12/2020 “Somatic mutations and clonal hematopoiesis in cardiovascular and metabolic disease”. Icahn School of Medicine at Mount Sinai – Cardiovascular Research Center Webinar Series. New York, USA *Online*. [*Invited Lecture*]
- 10/2020 “Somatic mutations and clonal hematopoiesis in age-related cardiovascular and metabolic disease”. Adipose Tissue Metabolism and Cardiovascular Diseases Symposium, Université de Lausanne, Switzerland. *Online*. [*Invited Lecture*]
- 10/2020 “Hematopoyesis clonal: ¿nuevo factor de riesgo cardiovascular?” Congreso SEC 2020, Spanish Society of Cardiology, Spain [*Invited Online Lecture*]
- 10/2020 “Hematopoyesis clonal e inflamación vascular: nuevas implicaciones en la enfermedad cardiovascular aterotrombótica” LXII Congreso Nacional SEHH, Spanish Society of Hematology and Hemotherapy, Spain [*Invited Online Lecture*]
- 09/2020 “Consequences of epigenetic gene mutations on CVD progression and therapeutic implications”. European Society of Cardiology Congress 2020. [*Invited Online Lecture*]
- 08/2020 “Somatic mutations and clonal hematopoiesis: emerging risk modifiers in atherosclerosis and beyond”. Cardiometabolism Virtual Seminar Series 2020. *Online*. [*Invited Lecture*]

- 05/2020 “Somatic mutations and clonal hematopoiesis in inflammation and cardiovascular disease”. Joint Meeting on Vascular Biology, Inflammation and Thrombosis, Medical University of Vienna, Austria. Online. [*Invited Lecture*]
- 01/2020 “Clonal Haematopoiesis in heart failure”. European Society of Cardiology Heart Failure Winter Meeting 2020. Les Diablerets, Switzerland. [*Invited Lecture*]
- 12/2019 "Somatic mutations and clonal hematopoiesis in cardiovascular disease: commonalities with cancer". Josep Carreras Leukemia Research Foundation. Badalona, Spain. [*Invited Lecture*]
- 11/2019 “TET2 - a new driver of age-related CVD”. American Heart Association Scientific Sessions 2019. Philadelphia, PA, USA. [*Invited Lecture*]
- 09/2019 “Clonal hematopoiesis - an emerging risk modifier in atherosclerosis”. European Society of Cardiology Congress 2019. Paris, France. [*Invited Lecture*]
- 07/2019 “Somatic mutations and clonal hematopoiesis as drivers of inflammation and cardiovascular disease. 39th Spanish Society of Pharmacology (SEF) Meeting. Las Palmas de Gran Canaria, Spain [*Invited Plenary Lecture*]
- 06/2019 “Mutaciones somáticas y hematopoyesis clonal: Nuevas implicaciones en la enfermedad cardiovascular”. XXXII Congress of the Spanish Arteriosclerosis Society (SEA). Valencia, Spain. [*Invited Lecture*]
- 02/2019 “Somatic mutations and clonal hematopoiesis in cardiovascular disease: commonalities with cancer”. Centro Nacional de Investigaciones Oncológicas (CNIO). Madrid, Spain. [*Invited Lecture*]
- 01/2019 “Somatic mutation-driven clonal hematopoiesis: a new player in atherosclerotic and cardiometabolic disease”. International Workshop: Clonal hematopoiesis and radiation-associated diseases. Radiation Effects Research Foundation (RERF). Hiroshima, Japan. [*Invited Lecture*]

PATENTS

Title: Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development

Inventors: Kenneth Walsh and **José Fuster**. Assignee: Boston University

US10041044B2/WO2018022982A1 Filed on: July 28, 2017 Priority Country: U.S.A.